We launched Discover Pharma to bring clarity, integrity, and relevance to life sciences reporting – and just one quarter in, we’re proud to say: the industry is listening.

Whether spotlighting RNA innovations, streamlining CGT manufacturing dialogue, or tackling strategic partnerships with clear-eyed reporting, we’ve become a trusted editorial home for industry insiders who value substance over spin.

The numbers, after less than three months, speak for themselves:

Summary:

Since launch, Discover Pharma has seen encouraging early traction, with 629 new users and 627 active users, indicating strong return engagement and relevance to our target audience. Our content is already resonating — particularly with readers seeking insight into pharma innovation and digital transformation. It also continues to grow day by day.

So far in June, we’ve welcomed 427 more active users, and the site has generated more than 3,000 page views, showing steady growth in awareness and visibility within the sector.

We anticipate continued growth as the Discover Pharma content library expands and targeted amplification (e.g. socials, a weekly newsletter) takes effect.

👥 Who You’re Reaching: A Strategically Engaged Pharma Audience

Discover Pharma attracts a growing and influential readership across key functions in pharma and biotech, with particularly strong engagement from teams driving innovation, data strategy, and medical insights.

Persona	Estimated Reach	Common Job Titles
Medical Affairs & Clinical	28%	Chief Medical Officer, Medical Affairs Director, MSL, VP Clinical Ops
Data, Digital & IT	25%	Chief Digital Officer, Director of Data Strategy, Head of Clinical IT
R&D / Regulatory	20%	VP Clinical Development, Regulatory Affairs Lead, RWE Director
Commercial Strategy & Market Access	17%	VP Commercial Strategy, Market Access Lead, Brand Director
Executive, Comms, & Innovation	10%	CEO, COO, Corporate Comms, Innovation Leads

Top Geographies: US, UK, EU5, Nordics

Typical Company Size: Mid-to-large pharma, biotech innovators, global CDMOs/CROs but keen to work with smaller companies too.

🌍 A Global and Strategic User Base

Our active user base is rapidly expanding across key pharmaceutical markets, with strong engagement from commercial and medical affairs professionals.

Where Our Users Are:

• United States: 38.8% – our largest and most commercially strategic audience
• United Kingdom: 31.1% – strong performance in a key European pharma hub
• India: 4.4% – rising interest from one of the world’s largest pharma manufacturing regions
• Germany, Spain, France: Each contributing 3–4% – steady growth across core EU markets
• Israel: 2.4% – a high-potential region for biotech and innovation

It is our aim to grow in Europe.

What our readers don’t want: Overly commercial, vendor-first content.
What they do want: Real insights, useful examples, and strategic inspiration.

But don’t just take it from us…

“Never have I had as collaborative a relationship with an editor. Liza digs deeper than the press release to create compelling stories.”
– Lisa Barbadora, CEO and founder, Barbadora INK

“Liza is a fantastic editor with a firm grasp of biotech. She’s supportive, communicative, and a joy to work with.”
– Jonathan Smith, pharmaceuticals freelance editor

“Her knowledge of pharma and health is deep. Liza is a great writer, super responsive, and keeps the plates spinning.”
– Mark Button, PR for IQVIA

“Liza represents the best in journalism — fast, curious, and able to translate complex concepts into accessible stories.”
– Brenda Nashawaty, PR executive

“She’s a responsive professional and knows the future of pharmaceuticals as well as the present.”
– Liat Simha, PR account manager

“The results say it all.”
– Julian Benkel, CEO

What’s next?

• A weekly newsletter
• A Q3 women-in-leadership spotlight
• A Day in the Life of…
• Continued roundtable coverage from leading events like CPHI, JP Morgan, and BIO-Europe
• A feedback-driven editorial calendar that reflects what you want to read — and what you need to know

Discover Pharma is the place to be if you want clear, well-researched, editorially-led coverage that doesn’t waste your time or your brand. Thank you – from our early days startup –  to all our contributors, readers, and early advocates who believe in us. We promise – we’re just getting started.